B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans

Sci Transl Med. 2024 Mar 6;16(737):eadi0295. doi: 10.1126/scitranslmed.adi0295. Epub 2024 Mar 6.

Abstract

Anti-CD20 therapy to deplete B cells is highly efficacious in preventing new white matter lesions in patients with relapsing-remitting multiple sclerosis (RRMS), but its protective capacity against gray matter injury and axonal damage is unclear. In a passive experimental autoimmune encephalomyelitis (EAE) model whereby TH17 cells promote brain leptomeningeal immune cell aggregates, we found that anti-CD20 treatment effectively spared myelin content and prevented myeloid cell activation, oxidative damage, and mitochondrial stress in the subpial gray matter. Anti-CD20 treatment increased B cell survival factor (BAFF) in the serum, cerebrospinal fluid, and leptomeninges of mice with EAE. Although anti-CD20 prevented gray matter demyelination, axonal loss, and neuronal atrophy, co-treatment with anti-BAFF abrogated these benefits. Consistent with the murine studies, we observed that elevated BAFF concentrations after anti-CD20 treatment in patients with RRMS were associated with better clinical outcomes. Moreover, BAFF promoted survival of human neurons in vitro. Together, our data demonstrate that BAFF exerts beneficial functions in MS and EAE in the context of anti-CD20 treatment.

MeSH terms

  • Animals
  • Antigen Presentation
  • Atrophy
  • Brain
  • Encephalomyelitis, Autoimmune, Experimental* / drug therapy
  • Gray Matter
  • Humans
  • Mice
  • Multiple Sclerosis, Relapsing-Remitting*
  • Neuroprotection